{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:45:17Z","timestamp":1792233917019,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Brentuximab vedotin (BV) represents a therapeutic advancement in the treatment of CD30-positive lymphomas, yet its clinical utility is often limited by BV-induced peripheral neuropathy (PN). Currently, evidence-based, BV-specific guidelines for the assessment and management of PN are scarce, resulting in variability in clinical practice. This study aimed to establish international expert consensus on the optimal assessment, monitoring and management strategies for BV-induced PN in patients with lymphoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A modified Delphi panel was conducted, engaging a total of 13 experts from eight different countries and representing haematology, neurology, dermatology, nursing and allied health disciplines. Panellists participated in three rounds of structured surveys, with statements developed based on a targeted literature review and guidance from an expert steering committee. Consensus was defined as\u2009\u2265\u200970% agreement\/disagreement. Consensus was achieved on 60\/87 (69%) statements across domains including risk factor assessment, symptom monitoring, pharmaceutical and non-pharmaceutical management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Key recommendations include routine risk profiling before BV initiation, use of validated assessment tools at baseline and throughout therapy, multidisciplinary collaboration, and early intervention for worsening PN. Areas of uncertainty and variability in PN management remain, particularly regarding management of intermediate-grade PN and optimal non-pharmacological strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These international consensus recommendations provide practical guidance for improving clinical management of BV-induced PN and highlight the importance of early identification, personalised care and multidisciplinary collaboration. Further research is needed to address persistent gaps and inform future clinical guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-026-11314-5","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:08:19Z","timestamp":1792231699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Expert consensus on the management of peripheral neuropathy in patients with lymphoma on brentuximab vedotin"],"prefix":"10.1007","volume":"34","author":[{"given":"Roser","family":"Velasco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Sanches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas A.","family":"Argyriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Cavaletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Domingo-Domenech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Foss\u00e5","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"G\u00e1llego P\u00e9rez-Larraya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia Miranda","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Molassiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Neder Ramires Abdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo L.","family":"Ortiz-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna B.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Scarisbrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Urwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"key":"11314_CR1","doi-asserted-by":"publisher","first-page":"104499","DOI":"10.1016\/j.critrevonc.2024.104499","volume":"204","author":"JS Abramson","year":"2024","unstructured":"Abramson JS, Stuver R, Herrera A et al (2024) Management of peripheral neuropathy associated with brentuximab vedotin in the frontline treatment of classical Hodgkin lymphoma. Crit Rev Oncol Hematol 204:104499","journal-title":"Crit Rev Oncol Hematol"},{"key":"11314_CR2","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol 30:2183\u20132189","journal-title":"J Clin Oncol"},{"key":"11314_CR3","unstructured":"European Medicines Agency. Adcetris 50 mg powder for concentrate for solution for infusion - Summary of Product Characteristics 2026."},{"key":"11314_CR4","unstructured":"Food and Drug Administration (FDA). Highlights of Perscribing Information. ADCETRIS\u00ae (brentuximab vedotin) for injection, for intravenous use. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125388Orig1s108lbl.pdf. First accessed: Sept 2025."},{"key":"11314_CR5","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T et al (2015) Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385:1853\u20131862","journal-title":"Lancet"},{"key":"11314_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ et al (2018) Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med 378:331\u2013344","journal-title":"N Engl J Med"},{"key":"11314_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2206125","volume":"387","author":"SM Ansell","year":"2022","unstructured":"Ansell SM, Radford J, Connors JM et al (2022) Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med 387:310\u2013320","journal-title":"N Engl J Med"},{"key":"11314_CR8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","volume":"33","author":"S Horwitz","year":"2022","unstructured":"Horwitz S, O\u2019Connor OA, Pro B et al (2022) The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol 33:288\u2013298","journal-title":"Ann Oncol"},{"key":"11314_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","volume":"404","author":"P Borchmann","year":"2024","unstructured":"Borchmann P, Ferdinandus J, Schneider G et al (2024) Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet 404:341\u2013352","journal-title":"Lancet"},{"key":"11314_CR10","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","volume":"5","author":"SM Horwitz","year":"2021","unstructured":"Horwitz SM, Scarisbrick JJ, Dummer R et al (2021) Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician\u2019s choice in cutaneous T-cell lymphoma: final data. Blood Adv 5:5098\u20135106","journal-title":"Blood Adv"},{"issue":"23","key":"11314_CR11","doi-asserted-by":"publisher","first-page":"6125","DOI":"10.3390\/cancers13236125","volume":"13","author":"R Velasco","year":"2021","unstructured":"Velasco R, Domingo-Domenech E, Sureda A (2021) Brentuximab-induced peripheral neurotoxicity: a multidisciplinary approach to manage an emerging challenge in Hodgkin lymphoma therapy. Cancers (Basel) 13:6125.\u00a0","journal-title":"Cancers (Basel)"},{"key":"11314_CR12","doi-asserted-by":"publisher","first-page":"6630","DOI":"10.1182\/bloodadvances.2023010622","volume":"7","author":"JT Bowers","year":"2023","unstructured":"Bowers JT, Anna J, Bair SM et al (2023) Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort. Blood Adv 7:6630\u20136638","journal-title":"Blood Adv"},{"key":"11314_CR13","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s00520-019-05023-5","volume":"28","author":"AA Argyriou","year":"2020","unstructured":"Argyriou AA, Bruna J, Anastopoulou GG et al (2020) Assessing risk factors of falls in cancer patients with chemotherapy-induced peripheral neurotoxicity. Support Care Cancer 28:1991\u20131995","journal-title":"Support Care Cancer"},{"key":"11314_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1634\/theoncologist.2015-0276","volume":"21","author":"I Gravanis","year":"2016","unstructured":"Gravanis I, Tzogani K, Hennik P et al (2016) The European Medicines Agency review of brentuximab vedotin (Adcetris) for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma or systemic anaplastic large cell lymphoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Oncologist 21:102\u2013109","journal-title":"Oncologist"},{"key":"11314_CR15","doi-asserted-by":"publisher","first-page":"204062071983902","DOI":"10.1177\/2040620719839025","volume":"10","author":"X Song","year":"2019","unstructured":"Song X, Wilson KL, Kagan J et al (2019) Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis. Ther Adv Hematol 10:2040620719839025","journal-title":"Ther Adv Hematol"},{"key":"11314_CR16","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","volume":"31","author":"B Jordan","year":"2020","unstructured":"Jordan B, Margulies A, Cardoso F et al (2020) Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 31:1306\u20131319","journal-title":"Ann Oncol"},{"key":"11314_CR17","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","volume":"38","author":"CL Loprinzi","year":"2020","unstructured":"Loprinzi CL, Lacchetti C, Bleeker J et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 38:3325\u20133348","journal-title":"J Clin Oncol"},{"issue":"10","key":"11314_CR18","first-page":"1","volume":"12","author":"CC Hsu","year":"2007","unstructured":"Hsu CC, Sandford BA (2007) The Delphi technique: making sense of consensus. Pract Assess Res Eval 12(10):1\u20138","journal-title":"Pract Assess Res Eval"},{"key":"11314_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/9781444392029","volume-title":"The Delphi technique in nursing and health research","author":"S Keeney","year":"2011","unstructured":"Keeney S, Hasson F, McKenna H (2011) The Delphi technique in nursing and health research. Wiley-Blackwell, Chichester"},{"key":"11314_CR20","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1177\/0269216317690685","volume":"31","author":"S J\u00fcnger","year":"2017","unstructured":"J\u00fcnger S, Payne S, Brine J et al (2017) Guidance on conducting and REporting DElphi studies (CREDES) in palliative care: recommendations based on a methodological systematic review. Palliat Med 31:684\u2013706","journal-title":"Palliat Med"},{"key":"11314_CR21","doi-asserted-by":"publisher","first-page":"e1004326","DOI":"10.1371\/journal.pmed.1004326","volume":"21","author":"WT Gattrell","year":"2024","unstructured":"Gattrell WT, Logullo P, van Zuuren EJ et al (2024) ACCORD (ACcurate COnsensus Reporting Document): a reporting guideline for consensus methods in biomedicine developed via a modified Delphi. PLoS Med 21:e1004326","journal-title":"PLoS Med"},{"key":"11314_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/ebnurs-2020-103303","volume":"23","author":"D Barrett","year":"2020","unstructured":"Barrett D, Heale R (2020) What are Delphi studies. Evid Based Nurs 23:68\u201369","journal-title":"Evid Based Nurs"},{"key":"11314_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1085-9489.2006.00078.x","volume":"11","author":"G Cavaletti","year":"2006","unstructured":"Cavaletti G, Jann S, Pace A et al (2006) Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 11:135\u2013141","journal-title":"J Peripher Nerv Syst"},{"key":"11314_CR24","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events v5.0 (CTCAE). Cancer Therapy Evaluation Program 2017."},{"key":"11314_CR25","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1007\/s00520-017-3772-y","volume":"25","author":"JM McCrary","year":"2017","unstructured":"McCrary JM, Goldstein D, Boyle F et al (2017) Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Support Care Cancer 25:3485\u20133493","journal-title":"Support Care Cancer"},{"key":"11314_CR26","doi-asserted-by":"publisher","first-page":"e16285","DOI":"10.1111\/ene.16285","volume":"31","author":"A Matthys","year":"2024","unstructured":"Matthys A, Bardel B, Le Bras F et al (2024) Rate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy. Eur J Neurol 31:e16285","journal-title":"Eur J Neurol"},{"key":"11314_CR27","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1136\/jnnp-2020-323124","volume":"91","author":"G Fargeot","year":"2020","unstructured":"Fargeot G, Dupel-Pottier C, Stephant M et al (2020) Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies. J Neurol Neurosurg Psychiatry 91:786\u2013788.\u00a0","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11314_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijnurstu.2018.05.004","volume":"85","author":"H Ullgren","year":"2018","unstructured":"Ullgren H, Tsitsi T, Papastavrou E et al (2018) How family caregivers of cancer patients manage symptoms at home: a systematic review. Int J Nurs Stud 85:68\u201379","journal-title":"Int J Nurs Stud"},{"key":"11314_CR29","doi-asserted-by":"publisher","first-page":"104289","DOI":"10.1016\/j.ijnurstu.2022.104289","volume":"133","author":"L Bonetti","year":"2022","unstructured":"Bonetti L, Tolotti A, Anderson G et al (2022) Nursing interventions to promote patient engagement in cancer care: a systematic review. Int J Nurs Stud 133:104289","journal-title":"Int J Nurs Stud"},{"key":"11314_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1529-8027.2007.00141.x","volume":"12","author":"G Cavaletti","year":"2007","unstructured":"Cavaletti G, Frigeni B, Lanzani F et al (2007) The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 12:210\u2013215","journal-title":"J Peripher Nerv Syst"},{"key":"11314_CR31","doi-asserted-by":"publisher","first-page":"e660","DOI":"10.1212\/WNL.0000000000012300","volume":"97","author":"P Alberti","year":"2021","unstructured":"Alberti P, Bernasconi DP, Cornblath DR et al (2021) Prospective evaluation of health care provider and patient assessments in chemotherapy-induced peripheral neurotoxicity. Neurology 97:e660\u2013e672","journal-title":"Neurology"},{"key":"11314_CR32","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1007\/s00520-017-3780-y","volume":"25","author":"J Le-Rademacher","year":"2017","unstructured":"Le-Rademacher J, Kanwar R, Seisler D et al (2017) Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel\/carboplatin-induced peripheral neuropathy in NCCTG\/Alliance clinical trials. Support Care Cancer 25:3537\u20133544","journal-title":"Support Care Cancer"},{"issue":"8","key":"11314_CR33","doi-asserted-by":"publisher","first-page":"e2424139","DOI":"10.1001\/jamanetworkopen.2024.24139","volume":"7","author":"T Li","year":"2024","unstructured":"Li T, Timmins HC, Mahfouz FM et al (2024) Validity of patient-reported outcome measures in evaluating nerve damage following chemotherapy. JAMA Netw Open 7:e2424139","journal-title":"JAMA Netw Open"},{"key":"11314_CR34","doi-asserted-by":"publisher","first-page":"1636923","DOI":"10.3389\/fonc.2025.1636923","volume":"15","author":"Y Yang","year":"2025","unstructured":"Yang Y, Liu SR, Wang L et al (2025) Frontline brentuximab vedotin-based therapy for newly diagnosed classical Hodgkin lymphoma: a meta-analysis of randomized controlled trials. Front Oncol 15:1636923","journal-title":"Front Oncol"},{"key":"11314_CR35","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1182\/bloodadvances.2022008420","volume":"7","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Bengston E, Redd R et al (2023) Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma. Blood Adv 7:1130\u20131136","journal-title":"Blood Adv"},{"key":"11314_CR36","doi-asserted-by":"publisher","first-page":"1252259","DOI":"10.3389\/fneur.2023.1252259","volume":"14","author":"Y Huang","year":"2023","unstructured":"Huang Y, Tan T, Liu L et al (2023) Exercise for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials. Front Neurol 14:1252259","journal-title":"Front Neurol"},{"key":"11314_CR37","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5737\/23688076351103","volume":"35","author":"J H\u00e9bert","year":"2025","unstructured":"H\u00e9bert J, Bergeron A-S, Claveau C (2025) Sensory re-education pilot program following chemotherapy-induced peripheral neuropathy in cancer patients. Can Oncol Nurs J 35:103\u2013113.","journal-title":"Can Oncol Nurs J"},{"key":"11314_CR38","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.3390\/cancers16142571","volume":"16","author":"KT Lee","year":"2024","unstructured":"Lee KT, Bulls HW, Hoogland AI et al (2024) Chemotherapy-induced peripheral neuropathy (CIPN): a narrative review and proposed theoretical model. Cancers (Basel) 16:2571.","journal-title":"Cancers (Basel)"},{"key":"11314_CR39","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1089\/jpm.2021.0512","volume":"25","author":"KF Jones","year":"2022","unstructured":"Jones KF, Wechsler S, Zulewski D et al (2022) Pharmacological and nonpharmacological management of chemotherapy-induced peripheral neuropathy: a scoping review of randomized controlled trials. J Palliat Med 25:964\u2013995","journal-title":"J Palliat Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11314-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11314-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11314-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:08:20Z","timestamp":1792231700000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11314-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["11314"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11314-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RV: Received honoraria, Speaker\u2019s Bureau participation and consulting services, as well as research funding, from Takeda. JAS: Received honoraria from Takeda; Speaker\u2019s Bureau participation for Takeda and Pint Pharma. AAA: Received honoraria, research funding and consulting services for Takeda, AbbVie, B\/O Jcare Pharma, Eli Lilly, GalleonBio, Lundbeck, Merck-Serono, Nura Bio, Orion Pharma, Roche, Teva. GC: Received honoraria from Takeda; consulting services for Italfarmaco SpA., UCB Pharma, Nura Bio and Augustine Therapeutics. EDD: Received honoraria from Takeda; consulting services for Takeda and Incyte; Speaker\u2019s Bureau participation for Takeda, Ideogen and BeOne. AF: Received honoraria from Takeda. JGPL: Received honoraria from Takeda and Johnson & Johnson; consulting services\/advisory role for Johnson & Johnson. AMR: Received honoraria from Takeda. AM: Received honoraria from Takeda and Chugai; received research funding from Helsinn. ANR: Received honoraria from Takeda. POR: Received honoraria from Takeda. SBP: Received honoraria from Takeda; consulting services for Luminate Medical. JS: Received honoraria from Takeda. LU: Received honoraria from Takeda. MW: Received honoraria and consulting services for Takeda. HMP: Received honoraria and provided advisory support for Takeda.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1116"}}